EGFR and non-small cell lung carcinoma: In clinics, EGFR inhibitors (EGFR-TKI) have already been used as a mature targeted medicine, such as Afatinib, Almonertinib, Brigatinib, etc., which are approved for the treatment of NSCLC [62].